Iron Deficiency Anaemia in Pregnancy and Postpartum: Pathophysiology and Effect of Oral versus Intravenous Iron Therapy

Table 1

Recently available intravenous (IV) iron preparations.

Name of the IV iron preparation	Status of registration	Indications	Test dose	Duration of infusion	Max dose in single infusion	Reference
^*Ferumoxytol (Feraheme, AMAG Pharmaceuticals, Inc., USA)	FDA approved	Treatment of iron-deficiency anaemia in adult patients with CKD**	None	1 minute	510 mg	[46, 47]
^*Ferric carboxymaltose (Ferinject, Vifor Pharma, Glattbrugg, Switzerland)	Approved in Europe,FDA-approval is sought	Treatment of iron-deficiency anaemia in adult patients	None	15 minutes	20 mg/kg with max dose of 1000 mg	[48, 49]
^*Iron isomaltoside (MonoFer, Pharmacosmos A/S, Holbaek, Denmark)	Approved in Europe FDA-approval is sought	Treatment of iron-deficiency anaemia in adult patients with CKD**	None	60 minutes	No max dose given at rate of 20 mg/kg	[50, 51]

FDA, Food and Drug Administration; CKD, chronic kidney disease; Max, maximum. ^*No available data in pregnancy; however, if the benefit of treatment is judged to outweigh the potential risk to the fetus, the treatment should be confined to second and third trimester of pregnancy. ^**Extended approval is sought.